Securities
Dec. 12, 2006
Biotech's Onus of Disclosure
FOCUS COLUMN - By Christopher H. McGrath and Oleg Cross - While headlines focus on the stock-option backdating scandals at many public companies, recent enforcement actions by the Securities and Exchange Commission confirm that public biotechnology companies continue to face industry-specific disclosure challenges under the federal securities laws.
By Christopher H. McGrath and Oleg Cross
While headlines focus on the stock-option backdating scandals at many public companies, recent enforcement actions by the Securities and Exchange Commission confirm that public biotechnology companies continue to face industry-specific disclosure challenges under the federal securities laws. Their disclosure obligations are shaped by the ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In